StocksCompany Analysis

EXAS Stock Surges 19% Amid Insider Trading and Analyst Optimism

7 months agoUS
EXAS Stock Surges 19% Amid Insider Trading and Analyst OptimismSource: quiverquant.com
EXAS stock (Exact Sciences) has seen a notable increase of 19% today, November 19, 2025. This surge is accompanied by high trading volume and significant activity from both insiders and institutional investors, alongside positive analyst ratings and price targets.

Key Insights

EXAS stock jumped 19% with approximately $645.4 million in trading volume.

Insider trading activity shows more sales than purchases over the last six months. Why this matters: Insider selling can sometimes be perceived negatively by investors, but it's crucial to analyze the context and overall market sentiment.

Hedge fund activity reveals mixed sentiment, with some firms increasing their positions substantially while others reduced theirs. Why this matters: Conflicting moves among institutional investors can create volatility and uncertainty for retail investors.

Analyst ratings are predominantly positive, with multiple firms issuing 'Buy' or 'Overweight' ratings. Why this matters: Positive analyst outlooks can boost investor confidence and attract more investment.

Recent analyst price targets range from $75 to $88, suggesting optimism about the stock's future performance. Why this matters: Price targets provide a benchmark for potential upside and influence investment strategies.

In-Depth Analysis

Exact Sciences ($EXAS) has experienced a significant stock surge, prompting a closer look at the underlying factors driving this movement.

Insider Trading Activity:

Over the past six months, insiders have predominantly sold shares. Key transactions include:

Katherine S Zanotti sold 15,207 shares for approximately $950,612.

Brian Baranick sold 2,858 shares for roughly $200,288.

James Herriott sold 3,000 shares for about $195,120.

James Edward Doyle sold 3,485 shares for approximately $182,399.

Track insider transactions on Quiver Quantitative's insider trading dashboard?ref=yanuki.com.

Hedge Fund Activity:

Institutional investors display varied strategies:

FMR LLC decreased its holdings by 8,241,935 shares (-30.6%).

WELLINGTON MANAGEMENT GROUP LLP reduced its stake by 6,677,809 shares (-55.6%).

CITADEL ADVISORS LLC increased its position by 3,506,084 shares (+805.1%).

CANADA PENSION PLAN INVESTMENT BOARD added 2,500,056 shares (+2439.1%).

ARK INVESTMENT MANAGEMENT LLC increased its holdings by 2,186,132 shares (+6072588.9%).

Monitor hedge funds' portfolios on Quiver Quantitative's institutional holdings dashboard?ref=yanuki.com.

Government Contracts:

$EXAS has received $592,152 in government contract award payments over the last year. Key awards include:

TESTING SERVICES FOR PATIENT CARE: $323,800

ONCOTYPE CANCER TESTING - OY 5 POP: $124,588

ONCOTYPE GENETIC TESTING SERVICES: $114,305

Analyst Ratings & Price Targets:

Wall Street analysts are largely optimistic:

Piper Sandler: Overweight rating, target price of $80.0 (11/11/2025)

Wells Fargo: target price of $85.0 (11/05/2025)

Baird: Outperform rating, target price of $88.0 (11/04/2025)

The median price target from 13 analysts is $80.0.

Track data on Quiver Quantitative?ref=yanuki.com.

FAQs

Q: What is driving the EXAS stock surge?

The surge is influenced by insider trading activity, hedge fund movements, positive analyst ratings, and optimistic price targets.

Q: Are insiders buying or selling EXAS stock?

Over the last six months, insiders have primarily been selling shares.

Q: What are analysts' price targets for EXAS?

The median price target from 13 analysts is $80.0, with targets ranging from $75 to $88.

Key Takeaways

Monitor insider trading activity for potential signals about company performance.

Keep an eye on hedge fund movements to gauge institutional sentiment.

Consider analyst ratings and price targets as part of your investment decision-making process.

Be aware of government contracts, which can provide a stable revenue stream.

Discussion

Do you think this trend will last? Let us know!

Share this article with others who need to stay ahead of this trend!

Related Articles

⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer